AbbVie Inc (ABBV) : Financial Architects Inc scooped up 6,216 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 25, 2016. The investment management firm now holds a total of 50,920 shares of AbbVie Inc which is valued at $3,304,708.AbbVie Inc makes up approximately 0.91% of Financial Architects Inc’s portfolio.
Other Hedge Funds, Including , Court Place Advisors boosted its stake in ABBV in the latest quarter, The investment management firm added 3,883 additional shares and now holds a total of 16,701 shares of AbbVie Inc which is valued at $1,083,895. AbbVie Inc makes up approx 0.61% of Court Place Advisors’s portfolio.Blb&b Advisors reduced its stake in ABBV by selling 145 shares or 0.21% in the most recent quarter. The Hedge Fund company now holds 67,936 shares of ABBV which is valued at $4,307,822. AbbVie Inc makes up approx 0.79% of Blb&b Advisors’s portfolio.Dearborn Partners reduced its stake in ABBV by selling 100 shares or 0.45% in the most recent quarter. The Hedge Fund company now holds 22,234 shares of ABBV which is valued at $1,409,858. AbbVie Inc makes up approx 0.12% of Dearborn Partners’s portfolio.Nadler Financial Group boosted its stake in ABBV in the latest quarter, The investment management firm added 3 additional shares and now holds a total of 9,803 shares of AbbVie Inc which is valued at $628,960. AbbVie Inc makes up approx 0.26% of Nadler Financial Group’s portfolio.
AbbVie Inc opened for trading at $65.27 and hit $66.4 on the upside on Friday, eventually ending the session at $66.23, with a gain of 2.33% or 1.51 points. The heightened volatility saw the trading volume jump to 1,05,25,016 shares. Company has a market cap of $107,118 M.
On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.